| Bioactivity | Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers[1][2][3]. |
| Invitro | Istiratumab (500 nM，24 小时) 在人胰腺癌细胞系中抑制 IGF-1 和 HRG 共刺激引起的AKT 激活[2]。Istiratumab (500 nM，24 小时) 抑制具有激活 KRAS 突变的胰腺癌细胞中 IGF-1 和 HRG 诱导的 AKT 磷酸化[2]。Istiratumab (500 nM, 24 h) 通过蛋白酶体途径诱导 IGF-1R 和 ErbB3 受体降解[2]。Istiratumab (1 μM，60 分钟) 阻断卵巢癌细胞系中 PI3K 和 MAPK 信号级联的激活[3]。 Western Blot Analysis[2] Cell Line: |
| Name | Istiratumab |
| CAS | 1509928-04-4 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kundranda M, et al. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). Ann Oncol. 2020 Jan;31(1):79-87. [2]. Camblin AJ, et al. Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer. Clin Cancer Res. 2018 Jun 15;24(12):2873-2885. [3]. Camblin AJ, et al. Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer. Sci Rep. 2019 Nov 14;9(1):16832. |